|
Enfortumab vedotin in the previously treated advanced head and neck cancer (HNC) cohort of EV-202. |
|
|
Honoraria - Elevar Therapeutics; Seagen |
Research Funding - Ascentage Pharma Group |
|
|
Consulting or Advisory Role - Astellas Pharma |
|
|
No Relationships to Disclose |
|
|
|
|
|
Stock and Other Ownership Interests - ImageMoverMD (I) |
Consulting or Advisory Role - IDEAYA Biosciences; Istari Oncology; Kura Oncology; Lilly; Merck; OncLive/MJH Life Sciences |
Research Funding - Astellas Pharma (Inst); Incyte (Inst); Kura Oncology (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Pfizer (Inst); Seagen (Inst); Sensei Biotherapeutics (Inst) |
|
|
No Relationships to Disclose |
|
|
Employment - Astellas Pharma |
|
|
Employment - Astellas Pharma |
|
|
Employment - Astellas Pharma |
Research Funding - Astellas Pharma |
Travel, Accommodations, Expenses - Astellas Pharma |
|
|
Consulting or Advisory Role - Astellas Pharma; Exelixis; Merck; Regeneron |
Research Funding - Alkermes (Inst); Genentech/Roche (Inst); Merck (Inst); Merck Serono (Inst); Merck Serono (Inst); Regeneron (Inst) |